Oak Ridge Investments LLC Has $1.28 Million Holdings in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)

Oak Ridge Investments LLC lowered its holdings in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) by 3.7% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 38,869 shares of the biopharmaceutical company’s stock after selling 1,509 shares during the period. Oak Ridge Investments LLC owned approximately 0.07% of Agios Pharmaceuticals worth $1,277,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. Acadian Asset Management LLC purchased a new stake in Agios Pharmaceuticals in the 2nd quarter worth about $37,000. Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Agios Pharmaceuticals by 21.4% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,058 shares of the biopharmaceutical company’s stock worth $94,000 after purchasing an additional 363 shares in the last quarter. CWM LLC boosted its holdings in shares of Agios Pharmaceuticals by 554.7% during the third quarter. CWM LLC now owns 2,167 shares of the biopharmaceutical company’s stock worth $96,000 after purchasing an additional 1,836 shares during the period. Quest Partners LLC grew its position in Agios Pharmaceuticals by 139.6% during the third quarter. Quest Partners LLC now owns 2,202 shares of the biopharmaceutical company’s stock valued at $98,000 after purchasing an additional 1,283 shares in the last quarter. Finally, Quantbot Technologies LP acquired a new position in Agios Pharmaceuticals in the 3rd quarter valued at approximately $146,000.

Insider Activity at Agios Pharmaceuticals

In related news, insider Tsveta Milanova sold 2,804 shares of the company’s stock in a transaction on Monday, January 6th. The stock was sold at an average price of $32.18, for a total value of $90,232.72. Following the completion of the transaction, the insider now directly owns 18,906 shares in the company, valued at approximately $608,395.08. This represents a 12.92 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 4.93% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

Several research firms have recently commented on AGIO. Leerink Partnrs cut shares of Agios Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Friday, September 27th. Scotiabank boosted their target price on Agios Pharmaceuticals from $53.00 to $75.00 and gave the company a “sector outperform” rating in a research note on Monday, December 9th. Leerink Partners downgraded Agios Pharmaceuticals from an “outperform” rating to a “market perform” rating and cut their price target for the stock from $60.00 to $56.00 in a research note on Friday, September 27th. Cantor Fitzgerald reissued an “overweight” rating on shares of Agios Pharmaceuticals in a research note on Wednesday, December 18th. Finally, StockNews.com raised shares of Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, November 9th. Five analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $56.33.

Agios Pharmaceuticals Price Performance

NASDAQ AGIO opened at $32.42 on Friday. The company’s fifty day moving average is $44.72 and its two-hundred day moving average is $45.07. Agios Pharmaceuticals, Inc. has a 52-week low of $20.96 and a 52-week high of $62.58. The firm has a market capitalization of $1.85 billion, a price-to-earnings ratio of 2.85 and a beta of 0.87.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.